The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

A second chikungunya vaccine may soon be available for travelers, officials say TUESDAY, May 13, 2025 (HealthDay News) — U.S.

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

The government of the United States has now advised its travelers who are of 60 years and above to not get a chikungunya ...